Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Eli Lilly and Company and Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on ...

Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

A deal for Ventyx would help Lilly compete in the promising space. If Ventyx’s experimental pills pan out, they would add to ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...

Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...

Eli Lilly and Company has entered a definitive agreement to acquire Ventyx Biosciences Inc., a San Diego-based clinical-stage ...